Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 Apr 1;71(13):477-483.
doi: 10.15585/mmwr.mm7113a1.

Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

Mark K Weng, Mona Doshani, Mohammed A Khan, Sharon Frey, Kevin Ault, Kelly L Moore, Eric W Hall, Rebecca L Morgan, Doug Campos-Outcalt, Carolyn Wester, Noele P Nelson
Practice Guideline

Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

Mark K Weng et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Hepatitis B (HepB) vaccines have demonstrated safety, immunogenicity, and efficacy during the past 4 decades (1,2). However, vaccination coverage among adults has been suboptimal, limiting further reduction in hepatitis B virus (HBV) infections in the United States. This Advisory Committee on Immunization Practices (ACIP) recommendation expands the indicated age range for universal HepB vaccination to now include adults aged 19-59 years. Removing the risk factor assessment previously recommended to determine vaccine eligibility in this adult age group (2) could increase vaccination coverage and decrease hepatitis B cases.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Kevin Ault reports grants received from the National Institutes of Health, consulting fees received from PathoVax, and leadership or fiduciary roles in American College of Obstetricians and Gynecologists, International Federation of Gynecology and Obstetrics, and Families Fighting Flu. Sharon Frey reports grants received from the National Institutes of Health and serving as chair of the HIV Vaccine Trials Network safety monitoring board. Eric W. Hall reports consulting fees from Merck for work unrelated to this manuscript. Kelly L. Moore reports that her employer receives unrestricted educational grant support from GlaxoSmithKline, Merck & Co., Inc., and a small unrestricted donation from Dynavax Technologies. No other potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Rates of reported acute hepatitis B virus infection, by age group — United States, 2004–2019 Source: https://www.cdc.gov/hepatitis/statistics/2019surveillance/Figure2.4.htm
See this image and copyright information in PMC

References

    1. Bruce MG, Bruden D, Hurlburt D, et al. Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose. Hepatology 2022. 10.1093/infdis/jiv748 - DOI - PMC - PubMed
    1. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67:1–31. 10.15585/mmwr.rr6701a1 - DOI - PMC - PubMed
    1. CDC. Viral hepatitis. 2019 viral hepatitis surveillance report. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm
    1. Klevens RM, Liu S, Roberts H, Jiles RB, Holmberg SD. Estimating acute viral hepatitis infections from nationally reported cases. Am J Public Health 2014;104:482–7. 10.2105/AJPH.2013.301601 - DOI - PMC - PubMed
    1. Roberts H, Ly KN, Yin S, Hughes E, Teshale E, Jiles R. Prevalence of HBV infection, vaccine-induced immunity, and susceptibility among at-risk populations: US households, 2013–2018. Hepatology 2021;74:2353–65. 10.1002/hep.31991 - DOI - PubMed

Publication types

Substances